Analysts Offer Predictions for MGRM FY2024 Earnings

Monogram Orthopaedics, Inc. (NASDAQ:MGRM) – Investment analysts at Roth Capital issued their FY2024 earnings estimates for shares of Monogram Orthopaedics in a research note issued on Monday, December 9th. Roth Capital analyst J. Wittes forecasts that the company will earn ($0.50) per share for the year. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Monogram Orthopaedics’ current full-year earnings is ($0.48) per share. Roth Capital also issued estimates for Monogram Orthopaedics’ Q4 2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.28) EPS and FY2028 earnings at $0.06 EPS.

Separately, Roth Mkm initiated coverage on Monogram Orthopaedics in a research report on Monday. They set a “buy” rating and a $4.00 price objective on the stock.

Monogram Orthopaedics Trading Down 3.0 %

Shares of NASDAQ MGRM opened at $2.60 on Wednesday. Monogram Orthopaedics has a 12-month low of $1.53 and a 12-month high of $4.90. The stock’s fifty day simple moving average is $2.27 and its two-hundred day simple moving average is $2.40. The stock has a market capitalization of $89.21 million, a PE ratio of -5.53 and a beta of 2.00.

Hedge Funds Weigh In On Monogram Orthopaedics

A number of large investors have recently made changes to their positions in MGRM. Geode Capital Management LLC raised its position in shares of Monogram Orthopaedics by 1,267.4% in the 3rd quarter. Geode Capital Management LLC now owns 210,144 shares of the company’s stock valued at $557,000 after purchasing an additional 194,776 shares during the last quarter. State Street Corp acquired a new position in Monogram Orthopaedics during the 3rd quarter valued at approximately $62,000. Finally, Barclays PLC purchased a new position in shares of Monogram Orthopaedics in the third quarter worth $29,000. 0.45% of the stock is owned by institutional investors and hedge funds.

About Monogram Orthopaedics

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.